Minimally Invasive Surgery for Pelvic Exenteration in Primary Colorectal Cancer

Naveena AN Kumar, MS, MCh, Sajith P. Sasi, MS, MCh, Rajesh S. Shinde, MS, MCh, Kamlesh Verma, MS, MCh, Pavan Sugoor, MS, MCh, Ashwin Desouza, MS, MCh, Reena Engineer, MD, Avanish Saklani, MS, FRCS

ABSTRACT

Background: Minimally invasive surgery (MIS) for pelvic exenteration is not a well-established technique. The aim was to assess the safety and feasibility of MIS for pelvic exenteration in locally advanced primary colorectal cancer and to compare the perioperative outcomes with open surgery.

Methods: This is a retrospective analysis of patients, who had undergone pelvic exenteration for primary colorectal adenocarcinoma from May 2013 to July 2018. The short-term outcomes like perioperative details and histopathological characteristics were compared between the two groups.

Results: MIS was performed in 23 patients and open pelvic exenteration was carried out in 72 patients. The mean operative time was significantly more in the MIS group (640 vs. 432 min, p = 0.00). The intraoperative blood loss (900 vs. 1550 ml, p = 0.00) and the requirement for blood transfusion (170 vs. 250 ml, p = 0.03) was significantly less in the MIS group. The overall morbidity (60% vs. 49%, p = 0.306) was comparable between the two groups. The median length of hospital stay in the MIS group was 11 d, compared to 12 d in the open surgery group, (p = 0.634). The rate of R0 resection (87% vs. 89%, p = 0.668) was comparable between the two groups.

Conclusion: MIS is feasible and safe for total pelvic exenteration and posterior exenteration in carefully selected locally advanced primary colorectal cancer, when performed by an experienced surgical team in high volume centers. An R0 resection with adequate margin can be achieved with good perioperative outcomes in MIS. Long-term oncological outcomes would require further follow up to confirm.

Key Words: Minimally invasive surgery, Pelvic exenteration, Rectal cancer, Laparoscopic surgery, Robotic surgery.

INTRODUCTION

Pelvic exenteration (PE) is indicated to achieve R0 resection in colorectal cancer (CRC) cases that are locally advanced as well as those that are locally recurrent.1–3 Open exenterative surgery, even though associated with more blood loss and major morbidity, offers long-term survival in appropriately selected patients.1–2,4 Minimally invasive surgery (MIS) with its perioperative advantages and improved visualization especially in male pelvises that are narrow and deep, may have significant benefits associated with it in PE.5 With advanced surgical instrumentation, refined surgical techniques, and ever increasing experience of the surgeon, many centers have explored the feasibility of MIS in PE;6,9 however, it has not become a well-established technique until recently.

Our hospital is one of the foremost referral centers for CRC in India.10 We regularly perform exenterative surgeries, extended resections and multivisceral resections for CRC cases.11–15 Our initial experience with regard to laparoscopic exenteration14–15 and the techniques of robotic exenteration16–18 were published previously.9 There were only a few studies, which had compared MIS with open PE (OPE).19 These studies had only a few patients in the MIS group with heterogeneous disease sub-types.20–22
We noticed a steady increase in the volume of patients undergoing exenterative surgeries at our institute every year (Figure 1). Hence, the aim of this study was to assess the feasibility and safety of MIS (laparoscopic and robotic) for PE in locally advanced primary CRC and also to compare the perioperative outcomes with conventional open surgery.

**MATERIALS AND METHODS**

**Patients**

Data was obtained from the prospectively maintained electronic database of the Gastrointestinal and Colorectal Services under the Department of Surgical Oncology. All consecutive patients who underwent PE for primary colorectal adenocarcinoma from May 2013 to July 2018 were evaluated. The patients with histological types other than adenocarcinoma and recurrent tumors, were excluded. Patients were denied surgery in accordance with the Beyond TME Collaborative Consensus guidelines suggesting certain contraindications.3 The absolute contraindications were medically unfit patients or patients with poor performance status, circumferential bone involvement and bilateral sciatic nerve involvement by tumor.3 The included patients were categorized into the MIS study group and the conventional OPE control group. The MIS group included laparoscopic and robotic surgery. Locally advanced primary rectal cancers with disease involving anterior and central pelvic compartments were carefully selected for MIS.23 The inclusion criteria for MIS was primary rectosigmoid/rectal cancers confined to anterior and central pelvic compartments without any extension into posterior or lateral pelvic wall on preoperative magnetic resonance imaging (MRI). Patients with previous multiple abdominal surgeries, patients who were suspected to have extensive small bowel adhesions and tumors with doubtful involvement of the lateral pelvic wall and presacral fascia/sacrum in the preoperative MRI pelvis were excluded from undergoing MIS.21

**Treatment**

As per protocol, all patients attending the colorectal clinic had to undergo standard evaluation with routine investigations, serum carcino-embryonic antigen (CEA) levels, colonoscopy, pelvic magnetic resonance imaging (MRI) and contrast enhanced computed tomography (CECT) of the thorax and abdomen. A multidisciplinary team was involved in the treatment plan. Locally advanced rectal cancer (LARC) patients (clinical stage T3-T4 or any N+) received neo-adjuvant concurrent chemo radiation therapy (NACRT). Following NACRT, patients were reassessed with MRI of the pelvis. If the mesorectal fascia (MRF) remained positive for tumor/node involvement, additional chemotherapy (4 cycles of Capecitabine/5FU and Oxaliplatin based chemotherapy) was administered. Patients with LARC, who were detected to have synchronous oligo-metastases, were subjected to treatment with short course radiotherapy (SCRT) and 3–4 cycles of neo-adjuvant chemotherapy. Patients with persistent involvement of adjacent organs on restaging MRI scan were planned for extended resections/PE in order to attain a margin clear R0 resection. Only patients with residual lateral pelvic lymph nodes following NACRT underwent lateral pelvic lymph node dissection (LPLND).

The type of pelvic exenteration performed was determined by the location, extent, and involvement of pelvic compartments.24 Total pelvic exenteration (TPE) referred to the resection of the rectum, sigmoid colon, internal reproductive organs, urinary bladder, and lower ureters.25 Posterior pelvic exenteration was defined as the resection of the rectum and the reproductive organs, sparing the bladder. Supralevator exenteration was defined as the removal of the rectum and bladder/reproductive organs and preserving the sphincter function with colorectal/colo-anal anastomosis.

Complications occurring within 30 days of surgery were defined as postoperative complications. Surgical complications were graded using the Clavien-Dindo (C-D) classification.26

**Surgical Technique**

Laparoscopic TPE was performed as described previously.14–15 We have also standardized the technique of robotic TPE (Figure 2).16 The steps of the abdominal part of surgery included retroperitoneal dissection (medial to lateral), inferior mesenteric artery and vein division, retro-
rectal space dissection all the way down to the origin of the levator ani muscle, medialization of the ureters, dissection of the pararectal and paravesical spaces up to the endopelvic fascia, retzius space dissection, division of the dorsal venous complex, transection of the urethra, division of the ureters, and transection of the sigmoid colon. The LPLND technique was also described previously, which included ureteric medialization, dissection around the iliac vessels, obliterated umbilical artery dissection, obturator nerve identification, and a radical dissection up to the pelvic floor to complete the standard template. The perineal part of the surgery was completed with or without plastic reconstruction comprising unilateral or bilateral VY advancement or pedicled flap depending on the size of the defect. The specimen was extracted through the perineal wound or through a small infra-umbilical incision in case of supralevator exenteration. The Bricker’s ileal conduit was performed by making a small midline infraumbilical incision. In patients who had previously undergone a transverse stoma, the stoma was retained as such and a uretero-sigmoid anastomosis was done after ensuring that the colon was stapled distal to the transverse stoma. Posterior exenteration by minimally invasive approach has its own advantages; however, it is technically demanding. We used standard port placement as used for TPE. Our technique of robotic posterior exenteration was published recently. The initial steps of surgery until dissection of the retro-rectal space were similar to MIS TPE. Further steps were as follows: division of the gonadal vessels, dissection of ureters until the uretero-vesical junction, dissection of perirectal space, dissection of parametral tissue, division of uterine vessels, dissection of vesico-uterine space, vaginal transection, dissection in the rectovaginal space, rectal transection/intersphincteric dissection in supralevator exenteration or perineal dissection if sphincters were sacrificed, and suture closure of the vaginal cut end.
Statistical Analysis

The short-term outcomes like perioperative details and histopathological characteristics were compared between the two groups. The comparison of qualitative variables was done by X-square or Fisher’s exact test and the comparison of continuous variables was done by the Mann–Whitney test. All p values reported were two-sided and 0.05 was considered as significant. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 20.0, for Windows (SPSS Inc., Chicago, Illinois).

Ethics

The ethical standards of the institutional research committee and the 1964 Helsinki Declaration and its later amendments were taken into account to make the study protocol. No formal consent was required for this study as this was a retrospective study and the institutional research committee approval was also not needed.

RESULTS

Twenty-three patients underwent minimally invasive PE and 72 patients underwent OPE. Thirteen patients underwent laparoscopic TPE and laparoscopic posterior exenteration was performed in 2 patients. Robotic TPE and robotic posterior exenteration was performed for 4 patients each. Three patients underwent supraveolar exenteration and 12 patients underwent LPLND in the MIS group. The preoperative characteristics are shown in Table 1. The MIS group had predominantly lower rectal tumors and more LPLNs metastases (Table 1). Characteristics related to patient demographics and tumor and treatment variables were similar in both the groups (Table 1).

The perioperative characteristics are shown in Table 2. The MIS group had a mean body mass index (BMI) of 23 kg/m². The details of surgery are shown in Table 2. No patient required sacrectomy in either of the groups. More than half of the patients (61%) required plastic reconstruction for perineal defect in the MIS group. The mean operative time was found to be significantly more in the MIS group (640 vs. 432 min, p = 0.00). The intraoperative blood loss (900 vs. 1550 ml, p = 0.00) and the requirement for blood transfusion (170 vs. 250 ml, p = 0.03) was significantly less in the MIS group. One patient, who had a doubtful lateral resection margin on MIS was converted to open surgery to achieve R0 resection. We also performed robotic intracorporeal ileal resection and anastomosis and uretero-ileal conduit anastomosis in 2 patients. The minor complication rates (Clavien-Dindo II) (35% vs. 29%, p = 0.902) and major complication rates (Clavien-Dindo IIIa (13% vs. 8.30%), IIIb and IV (13% vs. 10%, p = 0.902) were comparable between the MIS and OPE groups respectively. Out of the 14 patients with complications in MIS group, only 3 patients (21%) required exploratory laparotomy, while the other patients were managed conservatively with radiological/local surgical interventions (21%) or with regular wound dressings and antibiotics (58%). The rate of paralytic ileus was low in MIS compared to OPE group (4% vs.14%, p = 0.384), which was statistically not significant due to the low number of patients in the MIS group. The MIS group had a median duration of hospital stay of 11 days vs. 12 days in the OPE group; however, this was not statistically significant.

The histopathological characteristics are described in Table 3. The rates of R0 resection (87% vs. 89%, p = 0.668), circumferential resection margin (CRM) positivity (13% vs. 11%, p = 0.668), mean pelvic lymph node yield (13 vs. 15, p = 0.417), lymph node positivity (39% vs. 38.8%, p = 0.983) and other histopathological characteristics were comparable between the MIS and OPE groups respectively. The circumferential resection margin was involved in 13% (3 of 23) and 9% (6 of 66) patients with MRI positive mesorectal fascia in the MIS and OPE groups respectively.

At a median follow up of 13.6 months (1–75 months), no local recurrence and 3 distant recurrences were noted in the MIS group, as compared to 8 local recurrences and 27 distant recurrences in the OPE group (p = 0.031). The estimated two-year disease-free survival was 73.50% in the MIS group and 60.90% in the OPE group, which was statistically not significant.

DISCUSSION

MIS has become an acceptable treatment modality for locally advanced CRC as confirmed by many randomized controlled trials.27–30 The utilization of MIS for PE has been explored by many centers.6–8 However, current literature on comparison of MIS and OPE includes only small case series and retrospective reports.9–31 A recent systematic review of four retrospective studies by the PelvEx Collaborative group, reported the feasibility of MIS with good perioperative outcomes in selected cases.19 However, all of the current reports have a small sample size and there was heterogeneity in the study.20–22 31 In this comparative analysis, we studied 23 minimally invasive approaches and 72 conventional OPE, which to our knowledge is the...
| Characteristics                              | Total (n = 95) (%) | MIS (n = 23) (%) | OPE (n = 72) (%) | P value |
|---------------------------------------------|-------------------|-----------------|-----------------|---------|
| Age (year), mean (range)                   | 40 (45–71)        | 45 (21–64)      | 45 (19–71)      | 0.924   |
| >40                                         | 56 (59)           | 16 (70)         | 40 (56)         | 0.234   |
| <40                                         | 39 (41)           | 7 (30)          | 32 (44)         |         |
| Sex                                         |                   |                 |                 |         |
| Male                                        | 50 (53)           | 14 (71)         | 36 (50)         | 0.363   |
| Female                                      | 45 (47)           | 9 (39)          | 36 (50)         |         |
| Site                                        |                   |                 |                 |         |
| Rectum                                      | 84 (88)           | 22 (96)         | 62 (86)         | 0.384   |
| Rectosigmoid/sigmoid                        | 11 (12)           | 1 (4)           | 10 (14)         |         |
| Distance from anal verge (cm), mean (range) | 4.69 (0–20)       | 3 (0–11)        | 5.24 (0–20)     | 0.011*  |
| <5 cm                                       | 62 (65)           | 20 (87)         | 42 (58)         | 0.024*  |
| >5 cm                                       | 33 (35)           | 3 (13)          | 30 (42)         |         |
| Histology                                   |                   |                 |                 |         |
| WD/MD                                       | 67 (70)           | 18 (78)         | 49 (68)         | 0.502   |
| PD                                          | 28 (30)           | 5 (22)          | 23 (32)         |         |
| cT4a                                        | 37 (39)           | 8 (35)          | 29 (40)         | 0.674   |
| cT4b                                        | 51 (54)           | 13 (57)         | 38 (53)         |         |
| cN1 and above                               | 93 (98)           | 22 (96)         | 71 (99)         | 0.979   |
| cN0                                         | 2 (2)             | 1 (4)           | 1 (1)           |         |
| MRF involved                                | 92 (97)           | 22 (96)         | 70 (97)         | 1.00    |
| MRF free                                    | 3 (3)             | 1 (4)           | 2 (3)           |         |
| LPLN involved                               | 37 (39)           | 13 (57)         | 24 (33)         | 0.047*  |
| CEA (ng/mL), median (range)                 | 6 (1–1774)        | 5.5 (2–115)     | 6.1 (1–1774)    | 0.896   |
| >5                                          | 55 (58)           | 13 (56)         | 42 (58)         | 0.878   |
| Neo-adjuvant Rx                             | 92 (97)           | 23 (100)        | 69 (96)         | 0.757   |
| NACRT                                       | 72 (76)           | 19 (83)         | 53 (74)         | 0.550   |
| SCRT                                        | 15 (16)           | 4 (17)          | 11 (15)         | 0.809   |
| NACT                                        | 61 (64)           | 15 (65)         | 46 (64)         | 0.908   |

**Post neo-adjuvant status**

| Response status                           |                 |                 |                 |         |
|-------------------------------------------|-----------------|-----------------|-----------------|---------|
| Stable and Partial                        | 70 (76)         | 16 (76)         | 54 (76)         | 0.535   |
| Progression                               | 22 (24)         | 5 (24)          | 17 (24)         |         |
| CEA (ng/mL), median (range)               | 2.95 (1–68)     | 2.5 (1.37–9.66) | 3.4 (1–68)     | 0.391   |
| >5                                        | 55 (58)         | 13 (56)         | 42 (58)         |         |
| MRF involved                              | 89 (94)         | 23 (100)        | 66 (92)         | 0.178   |
| cM1                                       | 14 (15)         | 2 (9)           | 12 (17)         | 0.548   |
| Post RT delay (week), mean (range)        | 25 (5–119)      | 23 (5–63)       | 25 (6–119)      | 0.643   |
| >12 weeks                                 | 66 (76)         | 17 (74)         | 49 (76)         | 0.799   |

MIS, minimally invasive surgery; OPE, open pelvic exenteration; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; MRF, mesorectal fascia; LPLN, lateral pelvic lymph node; cM1, distant metastasis; CEA, carcino-embryonic antigen; Rx, treatment; NACRT, neo-adjuvant chemoradiotherapy; SCRT, short course radiotherapy; NACT, neo-adjuvant chemotherapy; RT, radiotherapy.

* = Statistically significant.
### Table 2.
Peri-Operative Characteristics

| Characteristics                              | Total (n = 95) (%) | MIS (n = 23) (%) | OPE (n = 72) (%) | P value |
|----------------------------------------------|--------------------|-----------------|-----------------|---------|
| Physical status (ASA), I                    | 63 (66)            | 14 (61)         | 49 (68)         | 0.526   |
| II and above                                 | 32 (34)            | 9 (39)          | 23 (32)         |         |
| BMI (kg/m²), mean (range)                    | 22.7 (15–36)       | 23 (16–36)      | 22.6 (15–31)    | 0.569   |
| > 25                                         | 29 (31)            | 7 (30)          | 22 (31)         | 0.929   |
| Hemoglobin (g/dL), mean                      | 11.15 (7–14)       | 11 (9–14)       | 11 (7–14)       | 0.925   |
| < 12                                         | 64 (67)            | 17 (74)         | 47 (65)         | 0.442   |
| Albumin (g/dL), mean                         | 3.7 (2.1–4.7)      | 4 (2.9–4.7)     | 3.7 (2.1–4.7)   | 0.008   |
| < 3.5                                        | 26 (27)            | 4 (17)          | 22 (31)         | 0.335   |
| Preoperative diversion stoma                 | 48 (51)            | 6 (26)          | 42 (58)         | 0.007   |
| Surgery                                      |                    |                 |                 |         |
| TPE                                          | 58 (61)            | 17 (74)         | 41 (57)         | 0.282   |
| Posterior exenteration                       | 38 (39)            | 6 (26)          | 31 (43)         |         |
| Sphincter preservation surgery (Supravelvator) | 29 (31)          | 3 (13)          | 26 (36)         | 0.067   |
| LPLND                                        | 35 (37)            | 12 (52)         | 23 (32)         | 0.080   |
| Posterior vaginal wall resection             | 16 (17)            | 4 (17)          | 12 (17)         | 1.00    |
| Plastic reconstruction                       | 26 (27)            | 14 (61)         | 12 (17)         | 0.00*   |
| Urinary conduit                              | 58                 | 15              | 41              |         |
| Ileum                                        | 56                 | 2               | 0               |         |
| Sigmoid colon                                | 2                  |                 |                 |         |
| Duration surgery (min), mean (range)         | 490 (180–800)      | 640 (420–800)   | 432 (180–660)   | 0.00*   |
| > 420 min                                    | 41 (62)            | 18 (95)         | 23 (49)         | 0.001*  |
| Blood loss, (mL), median                     | 1400 (150–4000)    | 900 (300–2600)  | 1550 (150–4000) | 0.00*   |
| > 1000mL                                     | 62 (65)            | 6 (26)          | 56 (78)         | 0.00*   |
| Blood transfused (mL), median (range)        | 250 (0–1500)       | 170 (0–1200)    | 250 (0–1500)    | 0.03*   |
| Complications (%)                            |                    |                 |                 |         |
| Clavien–Dindo grade                          | 49 (52)            | 14 (60)         | 35 (49)         | 0.306   |
| CD II                                        | 29 (31)            | 8 (35)          | 21 (29)         | 0.902   |
| CD IIIa                                     | 9 (9)              | 3 (13)          | 6 (8.3)         |         |
| CD IIIb and IV                               | 10 (11)            | 3 (13)          | 7 (10)          |         |
| CD V                                         | 1 (1)              | 0               | 1 (1.4)         |         |
| Type of complications                        |                    |                 |                 |         |
| Anastomotic leak                             | 9 (9.5)            | 2 (9)           | 7 (10)          | 1.00    |
| Bowel                                        | 5                  | 2               | 3               | 0.579   |
| Urinary                                     | 4                  | 0               | 4               | 0.384   |
| Pelvic collection                            | 9 (9.5)            | 1 (4)           | 8 (11)          | 0.289   |
| Paralytic ileus                              | 11 (12)            | 1 (4)           | 10 (14)         | 1.00    |
| Stoma complications                          | 3 (3.2)            | 2 (9)           | 1 (1)           | 0.227   |
| Conduit complications                        | 5 (5.3)            | 1 (4)           | 4 (6)           |         |
| Perineal wound infection                     | 24 (25)            | 8 (35)          | 16 (22)         |         |
| Mortality                                    | 1                  | 0               | 1               |         |
| Hospital stay (days), median (range)         | 12 (5–94)          | 11 (7–42)       | 12 (5–94)       | 0.634   |
| >14 days                                     | 33 (35)            | 7 (30)          | 26 (36)         | 0.619   |
| Re-admission in 30 days                      | 9 (9)              | 3 (13)          | 6 (8)           | 0.793   |

MIS, minimally invasive surgery; OPE, open pelvic exenteration; ASA, American Society of Anesthesiologists; BMI, body mass index; TPE, total pelvic exenteration; LPLND, lateral pelvic lymph node dissection; CD, Clavien–Dindo.

* = Statistically significant.
largest single center series of MIS for locally advanced primary colorectal adenocarcinoma.

We routinely perform laparoscopic and robotic TME for locally advanced CRC. The refinement of the surgical technique along with its standardization, better perioperative care, advances in interventional radiology, implementation of multidisciplinary team approach and careful patient selection have helped us to adopt MIS for PE in our center. The magnified view in the pelvis that is narrow and deep, the privilege of executing a meticulous dissection and careful transection of the small branches of internal iliac vessels, the controlled dissection of the distal part of ureters and uretero-vesical junction, and intersphincteric space in case of supralevator exenteration have encouraged us to perform more MIS procedures.

We emphasize on the careful selection of patients with a favorable anatomy and tumors with disease limited to the anterior pelvic organs for MIS. The presence of low-lying rectal tumors or lateral pelvic lymph node metastasis, whether neo-adjuvant chemo-radiotherapy/additional chemotherapy was given or not, response status to the neo-adjuvant treatment and preoperative diversion stoma did not influence our decision in considering MIS. We suggest performing the posterior and lateral dissection in the pelvis prior to the anterior dissection to avoid suspension of the bladder. The idea of performing ureteric transection towards the end of the abdominal part of the surgery is to facilitate the urine output monitoring and to prevent urine leak. The dorsal venous complex is divided at the last stage of the pelvic dissection and in case there is any

| Characteristics                          | Total (n = 95) (%) | MIS (n = 23) (%) | OPE (n = 72) (%) | P value |
|----------------------------------------|------------------|-----------------|-----------------|---------|
| Resection type, R0 (CRM involved)       | 84 (88)          | 20 (87)         | 64 (89)         | 0.668   |
| pT0                                    | 18 (19)          | 4 (17)          | 14 (19)         | 0.761   |
| pT1, pT2                               | 13 (14)          | 3 (13)          | 10 (14)         |         |
| pT3                                    | 25 (26)          | 8 (35)          | 17 (24)         |         |
| pT4                                    | 39 (41)          | 8 (35)          | 31 (43)         |         |
| pT4a                                   | 5 (5)            | 2 (9)           | 3 (4)           | 0.574   |
| pT4b                                   | 34 (36)          | 6 (26)          | 28 (39)         |         |
| pN0                                    | 58 (61)          | 14 (61)         | 44 (61)         | 0.983   |
| pN1 and above                          | 37 (39)          | 9 (39)          | 28 (38.8)       |         |
| LPLN involved                          | 3 (3.2)          | 0               | 3 (4)           | 0.757   |
| PNE                                    | 22 (23)          | 3 (13)          | 19 (26)         | 0.3     |
| pCR                                    | 14 (15)          | 2 (9)           | 12 (17)         | 0.548   |
| TRG < 2                                | 29 (31)          | 8 (35)          | 21 (29)         | 0.799   |
| Signet ring cell Histology             | 13 (14)          | 2 (9)           | 11 (15)         | 0.652   |
| LVI+                                   | 20 (21)          | 2 (9)           | 18 (25)         | 0.169   |
| PNI+                                   | 18 (19)          | 6 (26)          | 12 (17)         | 0.485   |
| EMVI+                                  | 9 (10)           | 2 (9)           | 7 (10)          | 1.00    |
| pM1                                    | 14 (15)          | 2 (9)           | 12 (17)         | 0.548   |
| Total mesorectal LNs, mean (range)     | 13 (0–5)         | 12 (4–28)       | 13 (0–5)        | 0.513   |
| Positive mesorectal nodes, mean (range)| 1.6 (0–28)       | 2 (0–28)        | 1.5 (0–17)      | 0.466   |
| U/L LPLN, mean (range)                 | 3 (1–5)          | 3 (1–5)         | 3 (1–5)         | 0.749   |
| Total Pelvic LNs, mean (range)         | 15 (0–78)        | 13 (4–28)       | 15 (0–78)       | 0.417   |

MIS, minimally invasive surgery; OPE, open pelvic exenteration; CRM, circumferential resection margin; LPLN, lateral pelvic lymph node; PNE, peri nodal extension; pCR, pathological complete response; TRG, tumor regression grade; LVI, lympho vascular invasion; PNI, perineural invasion; EMVI, extramural venous invasion; LN, lymph node; U/L, unilateral.
inadvertent bleeding, the intra-abdominal pneumo-peritoneum pressure is increased, the area packed with tape gauze and the bleeding vessel sutured during the perineal portion of the surgery.9,15

The mean operative time was significantly longer in the MIS group when compared to the OPE group, but this was still lesser time when compared to other reports (Table 4).5,21 The longer duration of MIS could be due to multiple factors such as the learning curve as our reports included all initial cases of MIS, the fact that surgical trainees as residents and fellows would perform the initial part of surgery and because of the extra time taken for intracorporeal urinary conduit, more number of LPLNDs and plastic reconstruction. The intraoperative blood loss and the requirement for blood transfusion was significantly less in MIS. The magnified view and meticulous dissection and transection of small branches of internal iliac vessels facilitated lesser blood loss.

The overall rate of complications in the MIS group is comparable to OPE and is similar to other reports (Table 4).19 These groups of patients are at risk for complications related to prolonged surgery and anesthesia like venous thromboembolism, extremity compression, peripheral neuropathies and hypothermia. However, we did not observe any increased incidence of these events in the MIS group. MIS reduces the hospital stay duration.19,34 The recent systematic review on MIS PE reported the median hospital stay as 22 d in the MIS group and 28 d in the OPE group.19 Our study reported a much shorter length of stay in the hospital in both the groups when compared to existing literature (Table 4),19 which might be because of the high-volume rate at our hospital (Figure 1). If the perineal complications rate in the MIS group were lesser, this would have further reduced the hospital stay duration. The length of hospital stay in the MIS exenteration group is more compared to any laparoscopic/robotic colorectal surgery mainly due to the complexity of the procedure itself.35 The high-volume rate in the MIS group would probably improve the perioperative outcomes and length of hospital stay in the future.

The rates of R0 resection, CRM positivity, mean pelvic lymph node yield and other histopathological characteristics were comparable between the MIS and OPE groups respectively; this was comparable to the existing literature as well (Table 4).19 We advise, not to hesitate to convert to open surgery if an oncologically safe resection is uncertain with MIS.

The highlights of our study were larger sample size compared to previous reports in the MIS group and no heterogeneous disease sub-types. The histopathological characteristics were also compared in this study. The limitations were the retrospective nature of the study, selection bias, unmatched groups and short term follow up. The postoperative recovery, quality of life and cost of surgery were also not assessed.

**CONCLUSION**

MIS is feasible and safe for total PE and posterior exenteration in carefully selected, locally advanced primary colorectal cancer.

---

**Table 4.**

Retrospective Reports of Minimally Invasive Surgery and Open Pelvic Exenteration in Locally Advanced Colorectal Cancer and Outcomes

| Study                  | Year | MIS/OPE (n) | Type of Pelvic Malignancy | Median Operative Time (min) | Median Blood Loss (mL) | Conversion Rate, n, (%) | Overall Morbidity (%) | Hospital Stay (days) | R0 Resection Rate |
|------------------------|------|-------------|---------------------------|----------------------------|------------------------|------------------------|----------------------|---------------------|-------------------|
| Present Study          | 2019 | 23/72 CRC   |                           | 640.00                     | 900.00                 | 1 (4)                  | 60.00                | 11.00               | 87.00             |
| Uehara K et al [20]    | 2016 | 9/58 CRC and others |                     | 935.00                     | 830.00                 | 1 (11.1)               | 66.7                 | 27.00               | 77.8              |
| Ogura A et al [5]      | 2016 | 13/18 CRC and others |                     | 829.00                     | 930.00                 | 0.00                   | 61.5                 | 29.00               | 100.00            |
| Yang K et al [19]      | 2015 | 11/37 CRC and others |                     | 565.2                      | 547.3                  | 0.00                   | 9.09                 | 15.3                | 100.00            |
| Winters BR et al [31]  | 2015 | 3/9 CRC and others |                     | 610.00                     | 550.00                 | 0.00                   | 33.34                | 7.34                | 66.7              |

CRC, colorectal cancer.
CRC cases, in patients with favorable anatomy, when performed by a surgical team with considerable experience and in high volume tertiary care centers. An R0 resection with adequate margin can be achieved with good perioperative outcomes in MIS. There is lesser intraoperative blood loss and decreased requirement for blood transfusion in MIS compared to open surgery. Long-term oncological outcomes would require further follow up to confirm.

References:
1. Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review. *Dis Colon Rectum*. 2013;56:519–531.
2. Bhangu A, Ali SM, Brown G, et al. Indications and outcome of pelvic exenteration for locally advanced primary and recurrent rectal cancer. *Ann Surg*. 2014;259:315–322.
3. Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. *Br J Surg*. 2013;100:1009–1014.
4. Pawlik TM, Skibber JM, Rodriguez-Bigas MA. Pelvic exenteration for advanced pelvic malignancies. *Ann Oncol*. 2006;13:612–623.
5. Ogura A, Akiyoshi T, Konishi T, et al. Safety of laparoscopic pelvic exenteration with urinary diversion for colorectal malignancies. *World J Surg*. 2016;40:1236.
6. Park SY, Choi G-S, Jun SH, et al. Laparoscopic salvage surgery for recurrent and metachronous colorectal cancer: 15 years’ experience in a single center. *Surg Endosc*. 2011;25:3551–3558.
7. Nagasue Y, Akiyoshi T, Ueno M, et al. Laparoscopic versus open multivisceral resection for primary colorectal cancer: comparison of perioperative outcomes. *J Gastrointest Surg*. 2013;17:1299–1305.
8. Nagasaki T, Akiyoshi T, Ueno M, et al. Laparoscopic salvage surgery for locally recurrent rectal cancer. *J Gastrointest Surg*. 2014;18:1319–1326.
9. Kumar N, Kammar P, Saklani A. Minimal invasive approach for beyond total mesorectal excision/extended resections in rectal cancer. *Mini-invasive Surg*. 2018;2:19.
10. Patil PS, Saklani A, Gambhire P, et al. Colorectal cancer in India: an audit from a tertiary center in a low prevalence area. *Indian J Surg Oncol*. 2017;8:484–490.
11. Pai VD, Jatal S, Ostwal V, et al. Multivisceral resections for rectal cancers: short-term oncological and clinical outcomes from a tertiary-care center in India. *J Gastrointest Oncol*. 2016;7:345–353.
12. Sinukumar S, Engineer R, Saklani A. Preliminary experience with lateral pelvic lymph node dissection in locally advanced rectal cancer. *Indian J Gastroenterol*. 2015;34:320–424.
13. Pai VD, Bhandare M, Saklani AP. Laparoscopic total mesorectal excision with en bloc resection of seminal vesicle for locally advanced rectal adenocarcinoma. *J Laparoendosc Adv Surg Tech A*. 2016;26:209–212.
14. Bhamre R, Pokharkar A, Shinde R, et al. Laparoscopic total pelvic exenteration for locally advanced carcinoma of the rectum - a video vignette. *Colorectal Dis*. 2018;20:161–162.
15. Pokharkar A, Kammar P, D’souza A, et al. Laparoscopic pelvic exenteration for locally advanced rectal cancer, technique and short-term outcomes. *J Laparoendosc Adv Surg Tech A*. 2018;28(12):1489–1494.
16. Kammar P, Bakshi G, Verma K, et al. Robotic total pelvic exenteration for locally advanced rectal cancer - video vignette. *Colorectal Dis*. 2018;20(8):731.
17. Sasi S, Rohila J, Kammar P, et al. Robotic lateral pelvic lymph node dissection (LPLND) in rectal cancer - video vignette. *Colorectal Dis*. 2018;20:554–555.
18. Kammar P, Sasi S, Kumar N, et al. Robotic posterior pelvic exenteration for locally advanced rectal cancer – a video vignette. *Colorectal Dis*. 2019;21(5):606.
19. The PelvEx Collaborative. *Surg Endosc*. 2018.
20. Yang K, Cai L, Yao L, et al. Laparoscopic total pelvic exenteration for pelvic malignancies: the technique and short-time outcome of 11 cases. *World J Surg Oncol*. 2015;13:301.
21. Uehara K, Nakamura H, Yoshino Y, et al. Initial experience of laparoscopic pelvic exenteration and comparison with conventional open surgery. *Surg Endosc*. 2016;30(1):132–138.
22. Martinez A, Filleron T, Vitse L, et al. Laparoscopic pelvic exenteration for gynaecological malignancy: is there any advantage? *Gynecol Oncol*. 2011;120(3):374–379.
23. Mukai T, Akiyoshi T, Ueno M, et al. Laparoscopic total pelvic exenteration with en bloc lateral lymph node dissection after neoadjuvant chemoradiotherapy for advanced primary rectal cancer. *Asian J Endosc Surg*. 2013;6:314–317.
24. Georgiou PA, Tekkis PP, Constantinides VA, et al. Diagnostic accuracy and value of magnetic resonance imaging (MRD) in planning exenterative pelvic surgery for advanced colorectal cancer. *Eur J Cancer*. 2013;49:72–81.
25. Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review. *Dis Colon Rectum*. 2013;56(4):519–31.
26. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 636 patients and results of a survey. *Ann Surg*. 2004;240(2):205e13. 2.
27. Guillou PJ, Quirke P, Thorpe H, et al. MRC CLASICC Trial Group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet.* 2005;365:1718–1726.

28. Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority randomised controlled trial. *Lancet Oncol.* 2014;15:767–774.

29. Van der Pas MH, Haglind E, Cuesta MA, et al. Colorectal Cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol.* 2013;14:210–218.

30. Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. *JAMA.* 2017;318:1569–1580.

31. Akiyoshi T. Technical feasibility of laparoscopic extended surgery beyond total mesorectal excision for primary or recurrent rectal cancer. *World J Gastroenterol.* 2016;22:718–726.

32. Winters BR, Mann GN, Louie O, et al. Robotic total pelvic exenteration with laparoscopic rectus flap: initial experience. *Case Rep Surg.* 2015;835425.

33. Sugoor P, Verma K, Chaturvedi A, et al. Robotic Versus laparoscopic sphincter preserving TME: a propensity case matched analysis. *Int J Med Robot.* 2018;14: e1965.

34. Park EJ, Cho MS, Baek SJ, et al. Long-term oncologic outcomes of robotic low anterior resection for rectal cancer: a comparative study with laparoscopic surgery. *Ann Surg.* 2015;261:129–137.

35. Braga M, Vignali A, Zuliani W, et al. Laparoscopic versus open colorectal surgery: cost-benefit analysis in a single-center randomized trial. *Ann Surg.* 2005;242(6):890–896.